

# Alligator Bioscience AB

www.alligatorbioscience.com



## Effective treatment of ischemia reperfusion injury in acute myocardial infarction

Alligator Bioscience is a drug discovery and development company. Based on its proprietary protein optimization technology FIND®, the company develops innovative protein based drug candidates for unmet medical needs in inflammation and cancer.

Alligator Bioscience has successfully collaborated with many pharma and biotech companies, including AstraZeneca, Bayer Healthcare and Wyeth.

### CONTACT DETAILS:

Paula Zeilon, VP BD  
paz@alligatorbioscience.com  
P: +46 46 2864280

ADC-1004 is a C5a receptor antagonist developed to prevent ischemia reperfusion (I/R) injury in acute myocardial infarction (AMI). The drug candidate significantly reduced infarct size in a clinical-like porcine model of AMI. Alligator Bioscience is seeking partnership with pharmaceutical companies for development and commercialization of the program.

### I/R Injury

I/R injury is a severe complication after e.g. acute myocardial infarction treated with PCI, and transplantation. I/R injury is damage that occurs when blood flow returns to tissue after a period of ischemia. Paradoxically, the restored blood flow results in inflammation and additional damage rather than normal function.

### Convenient Add-On Treatment Prior to Reperfusion


ADC-1004 blocks C5a receptors on neutrophils in circulation, before they enter the reperfused area and cause inflammation and damage. This allows the drug to be used as an effective and convenient intravenous treatment before PCI.

### Convincing Animal PoC

In a porcine model of AMI, the drug candidate significantly reduced infarct size and prevented the major portion of the heart damage expected to be caused by I/R injury. In the clinical setting, ADC-1004 is expected to reduce mortality, incidence of heart failure and incidence of malignant arrhythmias.

### High Medical Need

No treatment is currently available to reduce I/R injury. The medical need is substantial; more than 2 million patients suffer from acute myocardial infarction yearly.



I/R injury is an important contributor to organ damage